{"DataElement":{"publicId":"6640594","version":"1","preferredName":"Gene Amplification High Level Carcinoma Text","preferredDefinition":"The free text field to describe a high level DNA sequence rearrangement that results in the gain of one or more copies of a DNA segment that contains at least one gene amplified in cancer.","longName":"GEN_AMP_HIG_LEV_CARC_TXT","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6640585","version":"1","preferredName":"Gene Amplification High Level Carcinoma","preferredDefinition":"Any DNA sequence rearrangement that results in the gain of one or more copies of a DNA segment that contains at least one gene._A response indicating a high level._A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","longName":"5038954v1.0:6641768v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"5038954","version":"1","preferredName":"Gene Amplification","preferredDefinition":"Any DNA sequence rearrangement that results in the gain of one or more copies of a DNA segment that contains at least one gene.","longName":"C16605","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gene Amplification","conceptCode":"C16605","definition":"Any DNA sequence rearrangement that results in the gain of one or more copies of a DNA segment that contains at least one gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"232C45F0-1853-B694-E050-BB89AD43717B","latestVersionIndicator":"Yes","beginDate":"2015-10-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-10-28","modifiedBy":"ONEDATA","dateModified":"2015-10-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6641768","version":"1","preferredName":"High Level Carcinoma","preferredDefinition":"A response indicating a high level.:A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","longName":"C129474:C2916","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Level","conceptCode":"C129474","definition":"A response indicating a high level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"81B93EB6-873D-10A9-E053-F662850A20BA","latestVersionIndicator":"Yes","beginDate":"2019-02-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-12","modifiedBy":"ONEDATA","dateModified":"2019-02-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435027","version":"1","preferredName":"Gene","preferredDefinition":"A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule).","longName":"C16612","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB05-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81A31B12-B71B-48BF-E053-F662850A3F2F","latestVersionIndicator":"Yes","beginDate":"2019-02-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-11","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeDescription":"2/11/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5076316","version":"1","preferredName":"Descriptive 2000 Text","preferredDefinition":"The text that provides a description of a topic.","longName":"5076316v1.0","context":"ONC SDC Project","contextVersion":"1","type":"Non-enumerated","dataType":"ALPHANUMERIC","minLength":"1","maxLength":"2000","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234203","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F89B-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"FDA: FDA GUDID (Global Unique Device Identification Database)","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2651F0E1-431F-DD28-E050-BB89AD4365E5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-07","modifiedBy":"REEVESD","dateModified":"2015-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"High-Level (CN>8) And Focal (","type":"Preferred Question Text","description":"High-Level (CN>8) And Focal (CN>5) Amplifications of Genes Known to be Recurrently Amplified In Cancer","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81A2DE84-8859-5EBF-E053-F662850A0F2D","latestVersionIndicator":"Yes","beginDate":"2019-02-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-02-11","modifiedBy":"SOKKERL","dateModified":"2021-02-25","changeDescription":"2/11/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}